A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC)

NCT01871805 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

134

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG: Alectinib

Sponsor

Hoffmann-La Roche